Abstracts tagged "Disease Activity"

Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2568 • 2014 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Isabel Castrejón¹, Theodore Pincus¹, Daniel Wendling² and Maxime Dougados³, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose The Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) –an index of only patient-self-report measures - has been the most widely used measure in…
Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Ruediger Mueller¹, Johannes von Kempis¹, Michael H Schiff² and Sarah Haile³, ¹Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, ²University of Colorado, Denver, CO, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
Abstract Number: 1608 • 2014 ACR/ARHP Annual Meeting
Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis
Jill P. Buyon¹, R. Ramsey-Goldman², Richard Furie³, Chaim Putterman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁷Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Biomarkers of renal response in patients with systemic lupus erythematosus (SLE) may provide clues to pathogenesis and drive translation to treatment. This study was…
Abstract Number: 1324 • 2014 ACR/ARHP Annual Meeting
Predictors of Disease Relapse in Juvenile Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski² and Christina Kelsey³, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA
Background/Purpose Localized scleroderma (LS) is an autoimmune disease characterized by inflammation of the skin and underlying tissue leading tissue damage including atrophy, dyspigmentation, and fibrosis. …
Abstract Number: 866 • 2014 ACR/ARHP Annual Meeting
Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe⁴, David Albert⁵, Judith A. James⁶ and Joan T. Merrill³, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵AliveCor, Inc., San Francisco, CA, ⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heart rate variability (HRV) is a marker of vagus nerve activity and can be easily obtained with minimal technical expertise in the outpatient setting,…
Abstract Number: 556 • 2014 ACR/ARHP Annual Meeting
Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling³, ¹Rheumatology, CHRU, Besançon, France, ²Investigation Center, CHRU, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available. The aim…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Tuulikki Sokka¹, Hannu Kautiainen², Tuomas Rannio³, Juha Asikainen¹ and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Medcare Oy, Äänekoski, Finland, ³Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
Abstract Number: 2547 • 2014 ACR/ARHP Annual Meeting
The Impact of Primary Sjögren’s Syndrome on Female Sexual Function
Jolien F. van Nimwegen¹, Suzanne Arends¹, Greetje S. van Zuiden¹, Arjan Vissink², Frans G.M. Kroese¹ and Hendrika Bootsma¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose . Primary Sjögren's syndrome (pSS) is a chronic and disabling disease, characterized by sicca symptoms of the eyes and mouth as well as fatigue.…
Abstract Number: 2135 • 2014 ACR/ARHP Annual Meeting
Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy
Lewis Carpenter¹, Elena Nikiphorou², Sam Norton³, Keeranur Jayakumar⁴, Josh Dixey⁵ and Adam Young⁶, ¹Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ²School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, ⁵Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁶Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: Patients with moderate disease are an important, and often poorly studied, patient subgroup. The extent to which traditional DMARD therapies adequately control the disease…
Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting
Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
Abstract Number: 1314 • 2014 ACR/ARHP Annual Meeting
Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis
Raquel Campanilho-Marques¹, Beverley Almeida², Katie Arnold¹, Kiran Nistala³, Clarissa A Pilkington⁴ and Lucy R Wedderburn¹, ¹Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ²Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Centre for Rheumatology, University College London, London, United Kingdom, ⁴Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare condition affecting 3 children/million/year. Muscle and skin involvement are key features. The muscle symptoms are frequently the main…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].